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Intentions and Purpose of Research  
I intended to document the work of Christopher Tietze, director of the National Committee 
on Maternal Health, regarding the growing importance of research ethics and feminist activities 
which put under scrutiny biomedical research and, especially, contraceptive research. My 
purpose was to confirm the reputation Tietze had in the broad women’s health movement. There 
is, however, very little evidence that Christopher Tietze was close to being a feminist or was 
“pro-choice,” so to speak. Although, as I started to dig deeper into the National Committee on 
Maternal Health (NCMH) files, I realized that it would not be that simple. The NCMH files are 
chronologically organized and mix a variety of different types of documents. 
Only a few files refer to specific personal correspondence and give some insights on Tietze’s 
views. However, it is undeniable that Tietze had interaction with countless birth control activists 
in the world and had shared his perspective on women-controlled contraceptives and women’s 
rights to decide for themselves. Highly relevant to me were the letters he exchanged with Marie 
Lagroua Weil-Haillé, a historical figure of birth control in France who was at the origin of the 
French family planning association.
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 Moreover, Tietze demonstrated many times that he was a 
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strong advocate of personal and voluntary choices regarding birth control. He seemed to have 
little sympathy for coercion and rigid population programs in Third World countries.  
To sum up my first impressions of the NCMH files, I would say that I quickly decided to 
focus on other aspects of Christopher Tietze’s work which are related to my current research 
project with the INSERM in Paris.  Focusing on clinical trial protocols and the thousands of 
documents related to the better ways to conduct clinical experiments on contraceptives is a very 
promising approach to the NCMH files within the Population Council (PC) Archives. 
Hence, my research agenda changed radically and turned to the need to document how 
clinical trials were conducted and conceived by statisticians, medical personnel, birth control 
activists, and contraceptive manufacturers. It has considerably broadened my perspectives on the 
exploitation of the archives. In fact, I have had to reconsider my whole research agenda by 
focusing on the clinical experimentations Tietze had managed as a biostatistician. 
 These modifications in the research plan have greatly contributed to the need to readjust my 
investigations and to therefore produce less immediate results. I will need to develop a specific 
focus on the NMCH within the global experiments which were conducted in the 1950’s and 
1960’s with PC support. 
 
Research Methodology 
I conducted a thorough analysis of the entire NCMH collection dating from Tietze’s 
appointment as a director in January 1956 to its integration within the PC in 1966. These 
documents of more than ten years of research and correspondence are considerably relevant to 
my team’s research in France. To expand this study, I have looked at references to vaginal 
contraception in related Rockefeller University (RU) collections, some other PC files, and 1980’s 
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research and activism sponsored by the Rockefeller Foundation (RF). My purpose was to look 
for any references to vaginal contraception and interest in spermicides and venereal diseases.  
Vaginal contraception is a poorly documented segment of birth control history. In order to 
write forthcoming papers for international journals, I needed to reassess the entire field of 
research on vaginal contraception and the assumptions that led researchers to reconsider these 
products to prevent HIV infections in the Global South. Christopher Tietze conducted many 
different clinical programs on contraceptive efficiency in the 1960’s and was at the very center 
of the construction of clinical trials on contraceptive products. 
  As I was conducting research on microbicides (substances used as prophylactics for topical 
applications against infection by the HIV virus) and the history of scientific efforts against the 
AIDS pandemic, I found it particularly interesting to compare how clinical trials were developed 
in the first decade of large clinical trials on contraceptives in the 1950’s-1960’s with microbicide 
development in the 1990’s. There are stimulating similarities between research protocols 
invented in the 1960’s and the first clinical trials on HIV prophylaxis. There is also a striking 
continuity in the professional trajectory of some scientists. Although, I am still in a phase of data 
analysis, I have been able to reconnect some key participants of the Clinical Investigation 
Program (CIP)
2
 to more recent programs of the 1970’s, which renewed the scientific interest for 
vaginal contraception.  
Aquiles Sobrero, a director of research for the Margaret Sanger Research Bureau, was also a 
member of the long USAID-supported PARFR program which was one of the few organizations 
to fund research on spermicides in the 1970’s. The history of vaginal contraception allows us to 
comprehend the logic which guided contraceptive research. Vaginal contraception, especially 
spermicides, has often been treated with contempt and is generally considered “low-tech” and 
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rarely effective. It was, nevertheless, intensely supported by USAID as a way to distribute low 
cost simple contraceptives to African and Asian countries.  
The PC Archives at the Rockefeller Archive Center (RAC) helped document the gradual loss 
of interest in vaginal contraception in the 1960’s. The shift to oral contraception is not only 
relevant as a major societal fact, but is also a complex process which is related to clinical 
experimentations and the scientific validation of oral contraception and IUDs. The CIP program 
helped demonstrate that vaginal contraception was quite ineffective compared to other means of 
contraception. The National Committee on Maternal Health, the Population Council and PPFA 
all collaborated to evaluate different means of fertility control. They did prove that the IUD and 
the hormonal pill were much more efficient than the previous contraceptive jellies and foam 
tablets. It was the work of Tietze which permitted the development of true scientific evaluations 
of contraception. In doing so, he contributed to the move from vaginal contraception to more 
effective contraceptive technologies. 
Currently, I have approximately 1,600 documents from the NCMH files that relate to the 
work of Tietze. This variety of sources offers multiple dimensions of interpretation as I examine 
them. 
 
First Perspective:  
Clinical Testing and the Construction of Biostatistics in Human Reproduction 
 
As Marcia Meldrum demonstrated in her Ph.D. dissertation “Departures from the Design,” 
(New York University, 1994), Tietze accomplished considerable work by stabilizing the research 
protocols and norms of clinical testing in the U.S. He helped the CIP program to build a solid 
reputation and scientific credibility in the field of biomedical experimentation. Through the 
NCMH collection, we can investigate the role and institutionalization of research committees in 
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the 1950’s and early 1960’s, a time when research protocols and clinical trials had not been fully 
codified by laws and FDA regulations, but when norms were also produced by praxis and 
experimentation. 
 Valuable documents can be found on the “Margaret Sanger Research Bureau’s Committee on 
Approval of Chemical Contraceptive,” as well as on the “IPPF regulations and laboratory 
testing” in the 1950’s (Ad hoc testing committee). The spermicide testing documents give us 
incomparable insights of the decisions made regarding protocols and testing inside such research 
committees. Tietze contributed to the design of the statistical tools used to evaluate clinical trials 
and he also contributed to defining what would be the best form of data collecting among  
contraceptive users in the U.S., as well as in Third World countries.  
The NCMH files, mostly organized around Tietze’s work, are rich with hundreds of follow-
up forms, discussions and other records addressed to Tietze for reviewing. In fact, this was one 
of the principal activities Tietze conducted throughout his association with several important 
clinical testing programs (CIP or the IUD program conducted by the PC). This particular kind of 
clinical form allows us to picture how clinical testing was codified and how the practical 
problems of following-up contraceptive users, home visits, and contraceptive choices for the 
patients were dealt with by Tietze. His influence in the world of contraceptive clinical 
experiment is demonstrated by countless letters he exchanged with family-planning experts, 
activists and public servants. From French family-planning activists to Pakistan generals in 
charge of the population program in their country, Tietze shared his knowledge and views with 
many prominent personalities involved in contraceptive testing or in family planning activities. 
He provided the international population field with more reliable and scientific methods to 
evaluate contraception and, thereby provide women with efficient contraception.  
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Impartial and rigorous, Tietze demonstrated, through the CIP and other studies, that vaginal 
contraceptives are rarely reliable when it comes to a true “use-effectiveness” study of their 
capacities. Tietze, along with Mary Steichen Calderone from the PPFA or Aquiles Sobrero from 
the Margaret Sanger Research Bureau, helped design research protocols in the Third World and 
in the U.S, and constructed their experience with the concept of accumulated ”months-use” to 
evaluate contraceptive effectiveness. However, the major success of the CIP program was the 
attention it attracted to contraceptives and Planned Parenthood as an institution recognized for its 
capacity to conduct scientific clinical trials.  
Thanks to the NCMH archives, we can observe that in less than ten years Tietze faced 
multiple challenges regarding different technologies, which were becoming available to the 
general public, such as: spermicides, condoms, IUDs, and oral contraceptives. This ten year 
period, from 1956 through 1966, saw the activity of the NCMH become revived and 
demonstrated the acceleration of clinical testing and the slow imposition of scientific standards 
in the field of biomedical research on contraceptive technologies. The PC, while keeping its 
distance from Tietze during the first years, benefited greatly from his work and his 
correspondence with Council officers.  
The establishment of a biostatistics division within the Council was at last possible thanks to 
Tietze’s long accumulated experience. He finally joined the Council in 1966, the same year he 
became professor of biostatistics at Columbia. What we learn through a thorough review of the 
different research programs Tietze conducted, is that he was an excellent research coordinator 
and a person who went to the clinical testing sites to discuss matters with local staffs. He is a 
formidable example of and personalization of the institutionalization of clinical science in the 
1960’s. One of the most striking examples of his centrality in the field of birth control is that he 
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was constantly consulted by family planning associations, scholars and public servants in Third 
World countries to assess the validity of their own protocols and studies. 
That is why I consider him a “Global population scientist” in order to conceptualize the 
magnitude of his accomplishments. 
 
Second Perspective:  
Christopher Tietze, a Global Scientist before the Globalization of Health Policies 
 
Tietze and the NCMH gained rapidly an international reputation which brought him to work 
closely with major institutional partners in the Third World, the U.S., and also Japanese and 
European experts. General correspondence shows that Tietze exchanged his views on research 
and protocols with hundreds of key persons in the world and certainly influenced important 
members of several national population policies and family planning associations. 
It could be fascinating research to analyze the specificity of the exchanges Tietze had with 
personalities all around the world. I was first interested in his relationships with activists and, 
eventually feminists, but in fact the period was quite early to observe a neat increase in activist 
interest. However, there is a very interesting correspondence between Lagroua Weil-Hallé and 
Tierte, though it involves only eight documents. We can, however, observe that Tietze was very 
supportive and completely aware of the local efforts all over the world to foster new birth control 
policies. He was very supportive of women’s associations that tried to promote liberal 
regulations on birth control. 
The magnitude of Tietze’s correspondence is by far, the most impressive in the field of 
human reproduction. Tietze exchanged his views and expertise on population issues with people 
from dozens of different countries. Particularly interested in Eastern Europe, he was one of the 
few experts in the U.S. to possess strong professional connections with medical communities in 
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communist countries. He even participated in some scientific events in the Eastern Bloc.  When 
family planning programs started to blossom in the Indian subcontinent, Tietze became one of 
the key experts who public officers contacted to get more information about new technologies, 
but principally to construct new clinical experimentations.   
During his NCMH years, Tietze reviewed thousands of follow-up forms and questionnaires.  
Under his precise direction, most of the forms used for clinical investigations were standardized 
and adopted a common organization which was transposed to punched cards for ancient 
computers. Such follow-up forms were quite uniform from one country to another. For example, 
the Grafenberg ring investigation which Tietze conducted, because the inventor of a new “ring”, 
Jack Lippes, signed an agreement with the Population Council to evaluate its effectiveness and 
dangerousness
3
 used almost similar templates as the CIP program for vaginal contraception. The 
admission sheets and follow-up documents were basically the same in the United States and in 
other countries. In fact, he did, with the increasing presence of his wife, Sarah Lewitt, 
considerable work to offer standard questions and follow-up procedures to gather information on 
contraceptive use and the reality of contraception use in different parts of the world. 
Another important aspect of the NCMH work in contraceptive testing can be found in the 
Indian subcontinent. Tietze was in contact with most of the family planning leaders in Pakistan 
and India and helped them design their own clinical testing, for example, the recommendations 
he made to the Ceylon family planning association in 1961
4
 and the way he contributed to 
bettering their investigation. In 1959, he was working with the India family planning association 
to conduct clinical testing. He was also very active in commenting on academic work and 
investigations from fellow experts in the developing world. For example, we can find a thorough 
letter of comments to an Indian specialist, S.H. Agarwala,
5
 in which Tietze gave precious 
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comments to his Indian counterpart.  He also received follow-up forms from the Indian family 
planning association.
6
  
A large part of Tietze’s work consisted of routine exchanges of bibliographical references 
and papers that he wanted to circulate in the global family planning. Thousands of letters were 
sent to experts in India or the Philippines, and France and Mexico. It is fascinating to observe 
how Tietze managed to be one of the most important nexuses of an incipient globalized field of 
population and birth control research. While the PC was being built with patience, Tietze was 
free to have discussions with abortion specialists and sociologists twelve years before Roe 
Versus Wade. Tietze used his European background to animate a formidable exchange of 
information between experts from both sides of the Atlantic. His influence was consequently a 
determining factor in the making of a global contraceptive scientific field.  
The National Committee on Maternal Health was just a vehicle for Tietze to conduct clinical 
trials and to develop scientific standards and statistics. Through its institutional form and its 
connections with the PC it dramatically helped him advance his views on the contraceptive field 
and offered him the possibility to be an opinion that mattered in the global scientific community 
interested in birth control. 
 
Tietze and the CIP 
One of the first transnational clinical research programs on contraceptives was under Tietze’s 
guidance. The Contraceptive Investigation Program was designed by the IPPF and PPFA 
(Planned Parenthood Federation of America) to assess the efficacy of available contraceptives in 
the U.S. and abroad. The CIP allowed the development of large scale clinical trials using 
voluntary family planning patients to evaluate the effectiveness of different contraceptive 
methods. The difficulties were plenty and Tietze played the role of an unofficial research director 
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for countless experiments, dealing with several family planning associations. One important 
element was the multi-sited international tests that aimed at producing relevant data in different 
cultural settings. The program was conducted in seven different clinics in the United States, and  
also in Mexico City.  
The questions which were raised by the research protocols greatly influenced other studies. 
While Tietze was intensely involved in the CIP, he was also frequently asked to assess the 
statistical accuracy of other studies in the world. His main expertise, as documented in the 
NCMH files, was his capacity to build standardized follow-up forms for patients, consequently 
Tietze  participated in the design of much clinical research in the 1950’s and 1960’s. He can be 
considered the most influential scientist regarding clinical testing of contraceptives from 1955 to 
1970, since he oversaw most of the important clinical programs on contraception during that 
time period. 
Tietze knew that good statistical data was needed in order to get a better picture of which 
contraceptive really possessed a strong potential for global birth control. Of course, this was 
before the hormonal pill was available on the market. It was crucial at the end of 1950’s to 
collect more scientific information so as to address the growing anxiety of U.S. political leaders 
regarding population growth. This concern allowed the program to get some funding from 
private donors, but it never managed to attract NIH funds. The specificity of the CIP allowed 
Tietze and Mary Calderone to design model studies which could be exported in other contexts. 
Tietze used his experience in the CIP to foster clinical testing all over the world. The data 
collected in Cleveland, New York or San Antonio helped refine the quality of protocols and took 
into consideration the singularity of locations and populations. Foam tablets, spermicide jellies, 
and aerosol contraceptives were evaluated in the long run and most of them proved inefficient, 
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contrasting with numerous in vitro experiments. The definitive judgment on most vaginal 
contraceptives prepared family planning associations to adopt new contraceptive technologies, 
those possessing a statistically demonstrated effectiveness (Tietze later published his results in 
1968). The experience Tietze acquired during the CIP allowed him to expand his research to 
other continents and to advise dozens of researchers in India, Pakistan or Sri Lanka from 1961 to 
1965.
7
  
 
Durafoam Tablets and Foam Tablets Trials 
While Tietze was completing his data collection with the Planned Parenthood Federation of 
American clinics, he started a new clinical program with the IPPF regarding the acceptability of 
foam tablets in eight different countries, which were mostly Asian allies of the United States. 
The convergence of studies around 1960-1961 gave him the opportunity to assess different 
approaches regarding various cultural settings. It is remarkable that the complexity of managing 
global clinical trials was mastered by Tietze since he was only exchanging letters with his 
foreign colleagues. One quality Tietze possessed was his capacity to deal with contraceptive 
manufacturers.
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 His excellent relationships with tablet and jelly manufacturers promoted a better 
management of contraceptive shipments and distribution for family planning clinics.  
During the building-up phase of research protocols, Tietze was the real designer of the foam 
tablets trials. He made many corrections to the initial research protocols planned by IPPF and 
tried to take into consideration the complexity of local acceptance and preferences regarding 
contraceptive use. His role was even more important in this study than in the CIP study. As 
research director, Tietze was responsible for the trial design
9
 for the foam tablet acceptability 
study.  
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The IPPF’s main purpose was to document the possibility of developing the adherence to 
vaginal contraception among Third World women. It is remarkable that a considerable part of 
Tietze’s archives deal with the design of follow-up forms. The construction of the study was not 
only a statistical matter for Tietze, it was also part of a sociological work, in which he intended 
to collect cultural preferences and national differences regarding contraceptive behavior. Tietze 
had to design follow-up forms adaptable to different cultural settings, therefore creating 
standardized procedures for contraceptive clinical trials in Third World countries. However, the 
study was also conducted by Rotha Peers, an IPPF secretary who had difficulties maintaining 
good relationships with IPPF partners in India and Pakistan.  
This kind of problem emphasizes the difficulty of conducting clinical experimentation at the 
global level in the 1960’s. A comparative approach with current global clinical trials helps us 
understand how complex it must have been before the digital and logistic revolutions. Local 
family planning clinics were problematic in oversight and control from the United States, as was 
the use they made of the contraceptives which were sent to them. Some letters even mention 
custom problems, because custom officers in Pakistan were reluctant to release contraceptives. 
Tietze’s new role as a research director also involved more travel, for example, a NCMH- 
paid three months stay in Pakistan, during which he visited other Asian countries. For this 
particular program, Tietze also had to manage pure logistics problems, such as manufacturers 
sending their products to Third World countries without proper protection.
10
 It appears that 
custom relations between Pakistan and India posed a great challenge for the transport of 
contraceptive material as well. 
 Trials were also conducted in Kenya and South Africa with the same foam tablets used 
elsewhere. Interestingly, the required number of women to reach statistical significance could not 
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be obtained because of the difficulty of dispatching large quantities of tablets to each site. 
Egyptian doctors claimed that they were able to enroll five hundred women for the study, but 
there were only enough tablets for two hundred. This is one of the difficulties in the foam tablets 
acceptability study. Material conditions were not prone to foster easy access to contraceptive 
products to be tested in distant places. Nevertheless, Tietze benefited from the work of the IPPF 
secretary, Rotha Peers, who succeeded in maintaining a flow of tablets between different 
countries and managed to follow all the tablet shipments to make the study viable.   
Another impediment to the development of high-quality clinical trials in those days came 
from the physical impossibility of starting trials in ten different countries simultaneously. In this 
day and age, it is quite simple to provide trial sites with the proper equipment and the appropriate 
products, but in 1963, it was rather complex to get all the contraceptive gels to arrive at the same 
time. Further questions arise: “Is a history of clinical trial organization possible? What can we 
learn from Tietze’s effort to design reproducible protocols globally?”  
 Finally, patients’ reactions in the trials represent a fruitful possible comparison with current 
contraceptive and IST prophylaxis trials. Some patients in Kenya apparently tried to sell back the 
foam tablets which were given to them, in some other countries the smell of tablets was 
perceived as very offensive. Unexpected cultural preferences were already common in the 
1960’s. 
 
General Assessment and Publication Projects 
The research that I conducted on the biomedical study of spermicides and non-specific 
contraceptive agents has helped me design a new approach toward microbicide development and 
clinical experimentations in the Global South. Procedures, politics and organizations involved in 
contemporary contraceptive research in African or Asian countries remarkably resemble the 
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forms that took place in the 1950’s, when philanthropists and foundations had a considerable 
interest in testing their contraceptive recipes in Puerto Rico or in India. 
It appears that contraceptive research has been a “population control” initiative from the 
1950’s to the 1980’s. Patterns of actions and demographic goals have determined the ways ethics 
and experimentations were conceived. The burden of decades of conducting experiments in 
Southern countries and in poor settings in the United States has prejudiced further microbicide 
and contraceptive experimentation in the 1990’s. It is possible to develop a very stimulating 
research plan connecting local contraception to present biomedical research regarding Sexually 
Transmitted Infections (STI) prophylaxis. 
The importance of conducting research on spermicides experimentations in the 1950’s to 
document present scientific questions has proven to be bear substantial possibilities. I am now 
able to draw lines and connections between scientific personalities and institutions which have 
dominated the biomedical research agenda for decades and to therefore understand why 
microbicide research borrows so much to spermicides’ history. The similarities between the 
different eras of research, question some of the major certainties in contraceptive research, and 
also question the reality of ethics in research, since significant mistakes were sometimes made 
more than forty years after ethical questions were raised in the field, one example being, 
informed consent in Southern countries and the difficulty to translate not just words, but 
concepts to people. 
I now plan to write three papers on different aspects of my research. One would deal with 
clinical trials in contraceptive research in the perspective of a long history, comparing 
spermicides to microbicides and other new combinations of prophylactics/contraceptives. This 
paper will be submitted to Social History of Medicine and is currently being translated from 
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French to English. Another paper has already been published. Finally, I intend to devote an entire 
paper to Tietze’s research and his correspondence networks. 
The paper I am preparing will deal specifically with the construction of “forms.” The 
documents which were designed to collect people’s experiences are a central part of NCMH 
files.  My research at the RAC has afforded me the possibility to make essential comparisons 
between two rarely documented fields of scientific history: the history of vaginal contraception 
and the history of vaginal prophylaxis. 
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 Clinical Investigation Program, a research program conducted by Planned Parenthood Federation of 
America with the assistance of Christopher Tietze and the Margaret Sanger Research Bureau. 
3
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